CSL is arguably now an operational recovery story even though its share price is well above levels through most of 2019. During Covid, donors were apprehensive as virus fears loomed everywhere day to day plus of course, stimulus put plenty of $$ in people’s pockets but both of these headwinds have now largely been removed as donation centers again get busy which should flow down to increasing profits for the blood plasma company over the coming 6-12months.
- We believe CSL is offering excellent risk/reward in the $275 area.
MM remains bullish and long CSL
Add To Hit List
